News ArticleHindalco Industries Receives Independent ESG Rating of 68 from SES ESG Research
SES ESG Research assigned the rating based on public information without company engagement, reflecting Hindalco's ESG performance
Hindalco Industries Limited has been assigned an independent Environment, Social and Governance (ESG) rating of 68 by SES ESG Research Private Limited, a SEBI-registered ESG rating provider, based on publicly available information. The company did not engage the rating agency, and the ESG report was prepared independently. This rating reflects Hindalco's performance on ESG parameters and is disclosed as per SEBI regulations.
Hindalco Industries Limited
General / Other
Hindalco Industries Limited has been assigned an ESG rating of 68 by SES ESG Research Private Limited, a SEBI-registered rating provider. The rating evaluates the company's environment, social, and governance performance based on publicly accessible information without company involvement.
The ESG rating was voluntarily assigned by SES ESG Research Private Limited to Hindalco Industries Limited as per SEBI regulations governing disclosure requirements.
The company confirmed that it did not engage or commission the ESG rating agency; the rating was prepared independently using information available in the public domain.
This rating quantifies Hindalco's performance on Environment, Social, and Governance parameters, serving as an indicator of the company's ESG credentials.
Details of this ESG rating have been made publicly available on Hindalco's official website for investor reference and transparency purposes.
Highlights
- ESG rating of 68 assigned to Hindalco Industries by SES ESG Research Private Limited.
- SES ESG Research is a SEBI-registered ESG rating provider.
- Rating was prepared independently without company engagement.
- Assessment based solely on publicly available information.
- Information disclosed in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations.
- Details available on Hindalco's official website.
Key Data Snapshot
What happened
- Hindalco Industries Limited received a voluntary ESG rating of 68 from SES ESG Research Private Limited.
- The rating was assigned independently, based on publicly available data.
- The company did not engage the ESG rating provider.
Regulatory and governance context
- The rating disclosure follows Regulation 30 and Schedule III - Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The ESG rating provider is registered with the Securities and Exchange Board of India (SEBI).
Background and context
- ESG ratings assess corporate performance on environmental, social, and governance criteria.
- Independent ESG ratings can inform investors about a company’s sustainability practices without direct company influence.
Highlights
- ESG rating of 68 assigned to Hindalco Industries by SES ESG Research Private Limited.
- SES ESG Research is a SEBI-registered ESG rating provider.
- Rating was prepared independently without company engagement.
- Assessment based solely on publicly available information.
- Information disclosed in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations.
- Details available on Hindalco's official website.
Disclosures
- Regulation 30 (Schedule III - Part A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
